Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alk-Abello ASCHIX:ALKBC 92 3-Year EBITDA Growth Rate is 41.10% as of Mar. 2026, which is 104% above its 10-year median of 20.15. GuruFocus rates CHIX:ALKBC with a GF Score™ of 92/100 and a GF Value™ of kr210.47 (Modestly Overvalued). Among 1,135 Biotechnology companies, Alk-Abello AS ranks better than 79.12% on this metric.
During the past 12 months, Alk-Abello AS's average EBITDA Per Share Growth Rate was 34.60% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 41.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 38.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 15.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Alk-Abello AS was 51.60% per year. The lowest was -37.60% per year. And the median was 20.15% per year.
Alk-Abello AS (CHIX:ALKBc) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Alk-Abello AS 3-Year EBITDA Growth Rate Related Terms
CHIX:ALKBC vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Alk-Abello AS's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alk-Abello AS 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alk-Abello AS's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Alk-Abello AS's 3-Year EBITDA Growth Rate falls into.
Alk-Abello AS 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 41.10% mean?
Alk-Abello AS (CHIX:ALKBC) has a 3-Year EBITDA Growth Rate of 41.10% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Alk-Abello AS and its competitors. This is 104% above median its historical median of 20.15. According to the industry distribution chart, Alk-Abello AS ranks #237 out of 1135 companies in the Biotechnology industry, placing it in the top 20.9%.
Is Alk-Abello AS's 3-Year EBITDA Growth Rate too high?
Alk-Abello AS's current 3-Year EBITDA Growth Rate of 41.10% is 104% above median its 10-year median of 20.15. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.80. Alk-Abello AS's value of 41.10% is 177.7% above this industry median. Based on the distribution chart, Alk-Abello AS ranks #237 out of 1135 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alk-Abello AS has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alk-Abello AS ranks #237 out of 1135 companies for 3-Year EBITDA Growth Rate. This places Alk-Abello AS in the top 21% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.80. Alk-Abello AS's value of 41.10% is 177.7% above this benchmark. While the company's 10-year median is 20.15 vs. the industry median of 14.80, Alk-Abello AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.80, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alk-Abello AS's current 3-Year EBITDA Growth Rate of 41.10% is 177.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Alk-Abello AS and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alk-Abello AS's current 3-Year EBITDA Growth Rate is 41.10%, which is 104% above median its own 10-year median of 20.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (CHIX:ALKBC) is currently considered Modestly Overvalued. The stock's GF Value™ is kr210.47, compared to a current price of kr256.30 — trading 21.8% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 41.10%, which is 104% above median its 10-year median of 20.15 and 177.7% above the Biotechnology industry median of 14.80. Alk-Abello AS's overall GF Score™ is 92/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Alk-Abello AS (CHIX:ALKBC), the current 3-Year EBITDA Growth Rate is 41.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alk-Abello AS (CHIX:ALKBC) Overvalued in 2026?
Based on GuruFocus' analysis, Alk-Abello AS stock appears to be overvalued.
The current stock price of kr256.30 is trading 21.8% above its estimated GF Value™ of kr210.47.
GuruFocus considers Alk-Abello AS to be Modestly Overvalued.
Key valuation signals for CHIX:ALKBC:
3-Year EBITDA Growth Rate: 41.10% (104% above median its 10-year median of 20.15)
GF Value™: kr210.47 vs. price of kr256.30 (21.8% above fair value)
Industry Position: 177.7% above the Biotechnology median (#237 of 1135)
No single metric tells the full story. See the CHIX:ALKBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
92GF Score
Get the complete analysis for CHIX:ALKBC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ALKBC has been successfully added to your 
